Literature DB >> 19078048

Nonsteroidal antiinflammatory drugs and their effects.

L S Simon1.   

Abstract

New information about the mechanisms of action of nonsteroidal antiinflammatory drugs (NSAIDs) offers potential opportunities to minimize the complications of these commonly used drugs. Traditionally, the accepted mode of action of the NSAIDs has been the inhibition of prostaglandin synthesis through either reversible or irreversible binding to cyclooxygenase (COX). However, drugs that are weak prostaglandin synthesis inhibitors in vitro have been demonstrated to be equally as effective in vivo as other "stronger" COX inhibitors in treating inflammatory diseases, suggesting the importance of other actions of these drugs. Various NSAIDs have been used for years to palliate pain and inflammation in many different disease processes; unfortunately, they have not been demonstrated to alter the natural history of disease such as rheumatoid arthritis. Perhaps that is because prostaglandins do not play a large role in most inflammatory diseases; alternatively, it might be attributable to the inability of NSAIDs to exert their full effects because of their potential toxic reactions.An understanding of the effects of cyclooxygenase inhibition has been further complicated by the recently described second isoenzyme of prostaglandin synthase. One form of cyclooxygenase appears to be important in the maintenance of normal physiologic functions (COX-1), whereas the other form is induced primarily in sites of inflammation (COX-2). Even if inhibition of cyclooxygenase is only one mechanism of action for these drugs, with only some of the potential toxic effects modulated by the inhibition of prostaglandin synthesis such as inhibition of COX-1, an understanding of the actions of the two isoforms of cyclooxygenase is an important step in further delineating the inflammatory cascade. Ideally, the treatment of inflammation could be improved by inhibiting the effects of COX-2 without inhibiting COX-1 activity. Thus, some potential side effects of the NSAIDs might be alleviated. The presently available NSAIDs all affect both COX-1 and COX-2, although not equally. There are also data describing some of the NSAIDs as less toxic to the gastrointestinal mucosa because of their chemical composition. These data are typically based on in vitro experiments that use varying methodologies, making it difficult to compare the effects of any one NSAID between studies.This paper presents a brief review of several of the newly described effects of the NSAIDs and concentrates on the possible implications of the experimentally observed COX-2-selective effects of these clinically useful antiinflammatory agents.

Entities:  

Year:  1996        PMID: 19078048     DOI: 10.1097/00124743-199606000-00005

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  5 in total

Review 1.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 2.  Improving the gastrointestinal safety of NSAIDs: the development of misoprostol--from hypothesis to clinical practice.

Authors:  F E Silverstein
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

3.  Suppression of antibody-mediated arthritis in mice by Fab fragments of the mediating antibodies.

Authors:  S Yoshino; M Sasahara; Pilaiwanwadee Hutamekalin; K Yamaki; N Mizutani; H Kuramoto
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  Rofecoxib for osteoarthritis.

Authors:  S E Garner; D D Fidan; R Frankish; L Maxwell
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

5.  Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis.

Authors:  Ragia Hegazy; Mohamed Alashhab; Madiha Amin
Journal:  J Toxicol       Date:  2011-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.